Where great minds meet Honeycomb Connect
Home | My Cell | Help | Contact Us
Select Hive/Cell
People In Life Sciences (P.I.L.S.)
March 11, 2010  
People In Life Sciences (P.I.L.S.)
Connect Convention
News
Compliance Column
Executive Reports
Executive Profiles
Solutions Exchange e-Gallery
About Honeycomb Connect
Membership Benefits
Become a Sponsor
Contact Us
People In Life Sciences P.I.L.S. HomeNews
Executive Reports
Headlines Newsstand Executive Reports Solution News

December 2006

December 13, 2006

The Acsis Track & Trace Solution for Life Sciences is an end-to-end solution meeting today’s requirements while ensuring that today’s investment can easily be extended to meet future needs.   ...full story

December 13, 2006

Most companies identify growth as their number one priority. Accommodating growth and the change it implies places great pressure on core business processes and the systems that support them.   ...full story

 

November 2006

November 24, 2006

In the drug research industry, clinical trials are an indispensable part of developing safe medicinal products. They are also one of the most heavily regulated, time-consuming and costly stages of drug development. In an exclusive interview with Honeycomb Connect, one author of GCP guidelines and two pharmaceutical industry consultants share their opinions on the nature of ethical review and the key issues of concern in today’s regulatory environment.   ...full story

November 17, 2006

The credibility and replication of research findings evolve over time, as data accumulate. However, translation of postulated research promises to real-life biomedical applications is uncommon. In some fields of research, we may observe diminishing effects for the strength of research findings and rapid alternations of exaggerated claims and extreme contradictions—the “Proteus Phenomenon.”   ...full story

November 17, 2006

In an accompanying article published in PLoS Clinical Trials, the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) Research Group report the cardiovascular outcomes from their study [1]. The circumstances surrounding the termination of ADAPT were unusual and provide an important lesson for all clinical trialists, demonstr  ...full story

 
October 2006

September 2006

August 2006

July 2006

May 2006

April 2006

February 2006

October 2005

September 2005

August 2005

July 2005

April 2005

February 2005

January 2005

November 2004

October 2004

September 2004

August 2004

July 2004

June 2004

May 2004

April 2004

March 2004

February 2004

June 2002

Member Site Tour
User Name:

Password:


Forgot password?
My Cell | Help | Contact Us Privacy Policy | Legal disclaimers
Copyright © Honeycomb Connect